ERSPC, CAP, and ProtecT demonstrate PSA-detected prostate cancers have significant lead times, suggesting screening for prostate cancer may, on average, take 10–15 years or more to deliver meaningful benefits for men.6 Long acquisition times for new evidence poses additional challenges for health agencies making recommendations on screening. This evidence concerns the gene KLK3 and Familial prostate cancer.